For coronary in-stent restenosis in sirolimus-type drugs research.docVIP

For coronary in-stent restenosis in sirolimus-type drugs research.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
For coronary in-stent restenosis in sirolimus-type drugs research

 PAGE \* MERGEFORMAT 9 For coronary in-stent restenosis in sirolimus-type drugs research [Abstract] With the percutaneous coronary intervention in the clinical treatment of a wide range of applications, in-stent restenosis has become a constraining the development of this technology is an important factor in the advent of drug-eluting stents in this clinical challenge to bring new dawn. In this paper, the current widespread concern of drug-coated sirolimus-eluting stent and its derivatives as an overview of the progress of review. [Keywords:] coronary artery stenosis; sirolimus; derivatives; drug-eluting stent; restenosis ABSTRACT Along with percutaneous coronary intervention’s widespreadly clinical application, restenosis has become the major limitation to the effectiveness of the therapy. However the appearance of Drug  Eluting Stent has brought a fresh dawn to this difficult problem. This paper mainly introduces the research advances of sirolimus analogs as eluting  stent drugs. KEY WORDS Coronary artery stenosis; Sirolimus; Analogs; Drug  eluting stent; Restenosis Since 1977, percutaneous transluminal coronary angioplasty (percutaneous transcoronary coronary aqngioplasty, PTCA) used clinically, that is, created a new era in interventional cardiology. Over the next 20 years or so to PTCA for the interventional treatment of coronary heart disease-based technology, the rapid development of coronary revascularization as an important means of treatment. Every year there are currently more than 150 million patients underwent percutaneous coronary intervention, accounting for the percutaneous transluminal coronary surgery 75%. As the coronary stent in clinical use have gradually increased, in-stent restenosis (in  stent restenosis, ISR) rate is also increasing every year. How to effective treatment and prevention of ISR has become involved in another area of challenge, so the problem of restenosis, coronary intervention has become a constraining the d

您可能关注的文档

文档评论(0)

jiupshaieuk12 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:6212135231000003

1亿VIP精品文档

相关文档